Cargando…
Lymphocyte Subsets Show Different Response Patterns to In Vivo Bound Natalizumab—A Flow Cytometric Study on Patients with Multiple Sclerosis
Natalizumab is an effective monoclonal antibody therapy for the treatment of relapsing- remitting multiple sclerosis (RRMS) and interferes with immune cell migration into the central nervous system by blocking the α(4) subunit of very-late activation antigen-4 (VLA-4). Although well tolerated and ve...
Autores principales: | Harrer, Andrea, Pilz, Georg, Einhaeupl, Max, Oppermann, Katrin, Hitzl, Wolfgang, Wipfler, Peter, Sellner, Johann, Golaszewski, Stefan, Afazel, Shahrzad, Haschke-Becher, Elisabeth, Trinka, Eugen, Kraus, Joerg |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3282779/ https://www.ncbi.nlm.nih.gov/pubmed/22363732 http://dx.doi.org/10.1371/journal.pone.0031784 |
Ejemplares similares
-
Adaptive Immune Responses in a Multiple Sclerosis Patient with Acute Varicella-Zoster Virus Reactivation during Treatment with Fingolimod
por: Harrer, Andrea, et al.
Publicado: (2015) -
Cerebrospinal fluid CXLC13 indicates disease course in neuroinfection: an observational study
por: Pilz, Georg, et al.
Publicado: (2019) -
Chemokine CXCL13 in serum, CSF and blood–CSF barrier function: evidence of compartment restriction
por: Pilz, Georg, et al.
Publicado: (2020) -
The CXCL13/CXCR5-chemokine axis in neuroinflammation: evidence of CXCR5+CD4 T cell recruitment to CSF
por: Harrer, Christine, et al.
Publicado: (2021) -
Long-term immunological consequences of anti-CD20 therapies on humoral responses to COVID-19 vaccines in multiple sclerosis: an observational study
por: Moser, Tobias, et al.
Publicado: (2022)